Koroshetz, W
These advanced delivery systems are expected to improve the clinical outcomes of AS-IV and promote its widespread use in the prevention and treatment of liver disease
Brasil 691, Assis Chateaubriand - PR

Disclosures: Rosa Lombardi: Nothing to Disclose, Roberta Forlano: Nothing to Disclose, Annalisa Cespiati: Nothing to Disclose, Felice Cinque: Nothing to Disclose, Gabriele Maffi: Nothing to Disclose, Paola Dongiovanni: Nothing to Disclose, Daniela Bignamini: Nothing to Disclose, Paolo Francione: Nothing to Disclose, Giordano Sigon: Nothing to Disclose, Jian Huang: Nothing to Disclose, Pinelopi Manousou: Nothing to Disclose, Flora Peyvandi: Nothing to Disclose, Armando Tripodi: Nothing to Disclose, Anna Fracanzani: Nothing to Disclose 609 ANALYSIS OF CARDIOVASCULAR RISK FACTORS DURING THE TREATMENT OF METABOLIC DYSFUNCTION ASSOCIATED FATTY LIVER DISEASE WITH A LOW CARBOHYDRATE DIET Kwan Kit Cheung 1 Hongbo Du 1 , 1 Dongzhimen Hospital, Beijing University of Chinese Medicine Background: This study aimed to analyze cardiovascular risk factors during the treatment of metabolic dysfunction-associated fatty liver disease (MAFLD) with a low-carbohydrate diet
Biomimetics 8 (8), 592 (2023)